Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The analysis of investment activity ratios reveals a general contraction in asset efficiency from early 2022 through mid-2026, characterized by an initial decline followed by a period of relative stabilization. This pattern suggests a significant expansion of the asset base that initially outpaced revenue growth, a common occurrence during periods of aggressive capital investment.
- Net Fixed Asset Turnover
- A downward trend is observed from March 2022, where the ratio stood at 3.22, descending to a low of 2.53 by September 2024. Following this decline, the ratio stabilized, fluctuating within a narrow range between 2.59 and 2.72 through June 2026. This trajectory indicates a period of substantial investment in long-term fixed assets, with efficiency levels eventually plateauing as the newly acquired assets began contributing more consistently to revenue generation.
- Total Asset Turnover
- Total asset efficiency exhibited a similar contraction, moving from 0.62 in early 2022 to a low of 0.52 in March 2023 and September 2025. Throughout the remainder of the period, the ratio remained largely range-bound between 0.52 and 0.62. The lack of a strong recovery toward previous highs suggests that the overall growth in the total asset base has remained proportional to sales growth over the long term.
- Equity Turnover
- Equity turnover demonstrated the highest level of volatility among the analyzed ratios. After peaking at 3.40 in June 2022, the ratio experienced a sharp decline to 2.47 by March 2023. Although periodic recoveries occurred—reaching 3.17 in December 2023 and December 2024—a consistent downward trend is evident from early 2025 onward, ending at 2.35 in June 2026. This decline suggests an increase in shareholder equity that has grown faster than the corresponding revenue.
In summary, the convergence of these trends indicates a shift in the company's operational scale. The synchronized decline in fixed asset and total asset turnover points toward a strategic increase in capacity and infrastructure. The gradual decline in equity turnover further reflects a strengthening of the equity position relative to sales, resulting in a more conservative asset utilization profile compared to the baseline established in early 2022.
Net Fixed Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||
| Property and equipment, net of accumulated depreciation | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Net fixed asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Net fixed asset turnover
= (RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025)
÷ Property and equipment, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial trajectory of the organization is characterized by an aggressive expansion of the fixed asset base accompanied by a significant increase in top-line revenue. While both metrics exhibit strong growth over the analyzed period, the relationship between them reveals a transition from a high-efficiency asset utilization phase to a period of capacity build-out and subsequent stabilization.
- Revenue Growth Patterns
- Revenue demonstrates a substantial upward trajectory, increasing from 7,810 million USD in March 2022 to 22,974 million USD by June 2026. Although there were minor fluctuations in early 2022 and 2023, a period of accelerated growth began in mid-2024, with quarterly revenues consistently exceeding 11,000 million USD and eventually peaking at the end of the observed period.
- Fixed Asset Investment Trends
- Net property and equipment have undergone consistent expansion, growing from 9,103 million USD in March 2022 to 29,286 million USD in June 2026. This represents a more than threefold increase in the net fixed asset base, indicating sustained capital expenditure aimed at increasing production capacity or infrastructure.
- Net Fixed Asset Turnover Analysis
- The net fixed asset turnover ratio experienced an initial decline, falling from 3.22 in March 2022 to a low of 2.53 in September 2024. This downward trend suggests that the pace of investment in fixed assets initially outstripped the corresponding growth in revenue. However, following September 2024, the ratio stabilized and showed a slight recovery, ending at 2.72 in June 2026. This stabilization indicates that the revenue generated from the newly expanded asset base has begun to align with the scale of the investments, reflecting improved asset utilization following a period of heavy capital deployment.
Overall, the data indicates a strategic phase of heavy investment in long-term assets. The initial dip in the turnover ratio is a typical characteristic of an expansionary phase where assets are deployed before they reach full operational productivity. The subsequent stabilization of the ratio around 2.6 to 2.7 suggests the organization has reached a new equilibrium of operational efficiency at a significantly larger scale.
Total Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Total asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Total asset turnover
= (RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial trajectory from March 2022 through June 2026 is characterized by aggressive scaling in both operational output and the underlying asset base. While revenue has expanded significantly, the rate of asset acquisition has largely mirrored this growth, resulting in a total asset turnover ratio that remains relatively stable despite substantial absolute increases in scale.
- Revenue Growth Trends
- Revenue experienced a period of relative stability in 2022, followed by a steep acceleration starting in 2023. Quarterly revenues increased from 7,810 million USD in March 2022 to 22,974 million USD by June 2026. This sustained upward trend, particularly evident from 2024 onward, indicates a period of rapid commercial expansion.
- Asset Base Expansion
- Total assets grew from 46,919 million USD in March 2022 to 142,283 million USD by June 2026. The expansion shows a steady climb, with notable increases in asset accumulation starting in late 2023. This suggests substantial long-term investment in infrastructure or capacity to support the growing revenue demands.
- Total Asset Turnover Efficiency
- The total asset turnover ratio fluctuated within a narrow range between 0.52 and 0.62. A downward trend is observed between September 2022 (0.62) and March 2023 (0.52), reflecting a period where asset growth outpaced revenue realization. The ratio subsequently stabilized, showing a gradual recovery to a peak of 0.62 in March 2026 before adjusting to 0.56 in June 2026. The overall consistency of the ratio suggests that the company has successfully scaled its assets in proportion to its revenue growth, maintaining a stable level of asset utilization efficiency over the long term.
Equity Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Equity turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Equity turnover
= (RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025)
÷ Total Eli Lilly and Company shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance over the analyzed period is characterized by aggressive revenue growth and a substantial expansion of the equity base, which has collectively influenced the equity turnover ratio.
- Revenue Growth Trends
- Revenue experienced a consistent upward trajectory, increasing from 7,810 million US$ in March 2022 to 22,974 million US$ by June 2026. A significant acceleration in growth is observable starting in 2025, with quarterly figures rising from 12,729 million US$ in December 2023 to over 22 billion US$ in the final quarter of the sequence.
- Shareholders' Equity Expansion
- Total shareholders' equity showed a marked increase over the period. After remaining relatively stable between 8,545 million US$ and 11,220 million US$ from March 2022 to September 2023, the equity base expanded rapidly, reaching 33,879 million US$ by June 2026. The most pronounced growth occurred between March 2025 and June 2026, where equity more than doubled from 15,765 million US$ in December 2023 to its final peak.
- Equity Turnover Dynamics
- The equity turnover ratio exhibited a fluctuating yet generally downward trend in the latter half of the period. While the ratio reached a peak of 3.40 in June 2022 and showed resilience around 3.17 in December 2023 and December 2024, it entered a steady decline starting in March 2025 (2.91) and ending at 2.35 in June 2026. This contraction indicates that the growth in shareholders' equity has outpaced the growth in revenue during the final eight quarters, reflecting a decrease in the efficiency of equity utilization for revenue generation during this specific window.